DMAPT Dimethylamino Parthenolide|cas:791595-09-0|西域试剂

DMAPT Dimethylamino Parthenolide,98.0%

产品编号：Bellancom-16172| CAS NO：791595-09-0| 分子式：C₁₇H₂₇NO₃| 分子量：293.40

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-16172	￥600.00	杭州北京（现货）
Bellancom-16172	￥900.00	杭州北京（现货）
Bellancom-16172	￥1800.00	杭州北京（现货）
Bellancom-16172	￥2900.00	杭州北京（现货）
Bellancom-16172	￥4700.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

DMAPT Dimethylamino Parthenolide

产品介绍

DMAPT (Dimethylamino Parthenolide) 是Parthenolide (PTL) 的类似物，是具有口服活性的 NF-κB 抑制剂，对原发性急性髓性白血病细胞的LD₅₀ 值为1.7 μM。具有潜在的抗肿瘤和抗转移作用。

生物活性

DMAPT (Dimethylamino Parthenolide), an analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD₅₀ of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect.

体外研究

DMAPT treatment decreased constitutive NF-κB binding activity, inhibits cell proliferation and viability of PC-3 and DU145 cells.
Treatment of PC-3 and DU145 cells with 5 and 4 μM DMAPT, respectively, increases the population doubling times of PC-3 prostate cancer cells from 23.0 ± 5.0 h to 42.0 ± 3.0 h and of the DU145 cells from 20.4 ± 2.2 h to 72.5 ± 24.8 h.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	PC-3 and DU145 cells.
Concentration:	PC-3 cells (0, 2.5, 5 μM), DU145 cells (0 and 4 μM).
Incubation Time:	24 and 48 hours.
Result:	Decreased constitutive NF-κB binding activity, inhibits cell proliferation and viability of PC-3 and DU145 cells.

体内研究
(In Vivo)

Treatment with DMAPT (100 mg/kg, Oral gavage daily for 7 days) increases sensitivity of PC-3 tumor xenografts to X-rays.
DMAPT (100 mg/kg, Oral gavage thrice weekly from 42 to 300 days since birth) treatment slows normal tumor development in TRAMP mice, extending the time-to-palpable prostate tumor by 20%.
DMAPT further reduces the metastatic area below that of the water vehicle treatment group in lung tissues (0.10% ± 0.15 SD, 92% reduction, p = 0.0028) in TRAMP mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	PC-3 tumor xenograft in athymic nude mice.
Dosage:	100 mg/kg.
Administration:	Oral gavage daily for 7 days.
Result:	Increased sensitivity of PC-3 tumor xenografts to X-rays.

Animal Model:	Six-week-old male TRAMP mice.
Dosage:	100 mg/kg.
Administration:	Oral gavage thrice weekly from 42 to 300 days since birth.
Result:	Slowed normal tumor development in TRAMP mice, extending the time-to-palpable prostate tumor by 20%.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	PC-3 tumor xenograft in athymic nude mice.
Dosage:	100 mg/kg.
Administration:	Oral gavage daily for 7 days.
Result:	Increased sensitivity of PC-3 tumor xenografts to X-rays.

Animal Model:	Six-week-old male TRAMP mice.
Dosage:	100 mg/kg.
Administration:	Oral gavage thrice weekly from 42 to 300 days since birth.
Result:	Slowed normal tumor development in TRAMP mice, extending the time-to-palpable prostate tumor by 20%.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	PC-3 tumor xenograft in athymic nude mice.
Dosage:	100 mg/kg.
Administration:	Oral gavage daily for 7 days.
Result:	Increased sensitivity of PC-3 tumor xenografts to X-rays.

Animal Model:	Six-week-old male TRAMP mice.
Dosage:	100 mg/kg.
Administration:	Oral gavage thrice weekly from 42 to 300 days since birth.
Result:	Slowed normal tumor development in TRAMP mice, extending the time-to-palpable prostate tumor by 20%.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (426.04 mM; Need ultrasonic)

H₂O : 1.1 mg/mL (3.75 mM; ultrasonic and warming and heat to 40°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.4083 mL	17.0416 mL	34.0832 mL
5 mM	0.6817 mL	3.4083 mL	6.8166 mL
10 mM	0.3408 mL	1.7042 mL	3.4083 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (7.09 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.09 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (7.09 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.09 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (7.09 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.09 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。